NCT02781753View on ClinicalTrials.gov

Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Chinese Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 7, 2016

Primary Completion Date

August 2, 2016

Study Completion Date

April 12, 2017

Conditions
Healthy
Interventions
BIOLOGICAL

Human Serum Albumin/interferon alpha2b

Human Serum Albumin/interferon alpha2b fusion protein 300-1200 μg single dose S.C. at Day0

BIOLOGICAL

Peginterferon 180 μg single dose S.C.

Pegasys 180 mcg S.C. single dose on Day 0

Trial Locations (1)

100069

Beijing YouAn Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Tianjin SinoBiotech Ltd.

INDUSTRY

NCT02781753 - Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Chinese Healthy Volunteers | Biotech Hunter | Biotech Hunter